Our Pricing

Weight Loss Injections Without GP - Next Day Delivery

Accessing weight loss injections without GP appointments is now straightforward through UK-registered online pharmacies. At Cured Pharmacy, our UK prescribers conduct comprehensive clinical assessments online, enabling eligible patients to receive genuine MHRA-licensed treatments like Mounjaro, Wegovy, and Saxenda with discreet next-day delivery—no face-to-face GP visit required.

How to Get Weight Loss Injections Without Visiting Your GP

UK regulations permit registered online pharmacies to prescribe weight loss injections following a clinical assessment by a qualified prescriber. At Cured Pharmacy (GPhC 9012511), our process involves a confidential medical questionnaire reviewed by UK-registered prescribers who determine suitability based on your BMI, medical history, and weight loss goals.

The online consultation typically takes under three minutes to complete. If approved, your prescription is dispensed by our superintendent pharmacist Tarun Kumar (GPhC 2233073) and dispatched for next-day delivery in 100% discreet packaging. This service operates entirely within MHRA and GPhC guidelines, ensuring the same clinical rigour as traditional GP consultations whilst offering greater convenience.

Which Weight Loss Injection Is Most Effective?

Three GLP-1 receptor agonists dominate the UK weight loss injection market: tirzepatide (Mounjaro), semaglutide (Wegovy), and liraglutide (Saxenda). Clinical trial data reveals significant differences in efficacy. Tirzepatide demonstrated average weight reductions of 22.5% over 72 weeks in the SURPASS-3 trial, compared to 14.9% for semaglutide in the STEP-1 trial [1][2].

Mounjaro works through dual GIP/GLP-1 receptor activation, targeting two metabolic pathways simultaneously. This dual mechanism enhances insulin secretion, suppresses appetite more effectively, and slows gastric emptying. Wegovy and Saxenda utilise single-pathway GLP-1 activation, which remains highly effective for many patients but produces slightly lower average weight loss outcomes [1][3].

Your UK prescriber will recommend the most appropriate treatment based on your BMI, previous weight loss attempts, medical conditions such as type 2 diabetes, and tolerance for injection frequency. Saxenda requires daily injections, whilst Mounjaro and Wegovy are administered once weekly, which many patients find more convenient.

Clinical Trial Evidence for GLP-1 Treatments

The SURPASS clinical programme evaluated tirzepatide across multiple doses in over 6,000 participants. At the 15mg maintenance dose, participants achieved mean weight reductions exceeding 20% when combined with lifestyle modifications [1]. The STEP trials for semaglutide showed 68% of participants achieved at least 10% weight loss, with 50% reaching 15% or greater reductions [2].

Liraglutide, marketed as Saxenda, demonstrated more modest results in the SCALE trials, with average weight loss of 8-9% over 56 weeks [3]. All three medications require ongoing use to maintain weight loss, and discontinuation typically results in weight regain. These are long-term treatment options rather than short-term solutions.

What to Expect During Your Online Consultation

The clinical assessment for weight loss injections evaluates multiple factors beyond BMI. UK prescribers review your weight history, previous diet and exercise attempts, existing medical conditions including cardiovascular disease and thyroid disorders, current medications, and any history of pancreatitis or medullary thyroid carcinoma—both contraindications for GLP-1 treatments.

Eligibility criteria typically require a BMI of 30 or above, or 27 with weight-related comorbidities such as hypertension or type 2 diabetes. NICE guidelines recommend GLP-1 receptor agonists as part of a comprehensive weight management programme including dietary modification and increased physical activity [4].

If your prescriber determines you're not suitable for injectable treatments, they may recommend alternatives such as Orlistat, which works through fat absorption inhibition rather than appetite suppression. Orlistat is appropriate for patients who prefer oral medication or have contraindications to GLP-1 therapies.

Mounjaro, Wegovy, and Saxenda: Understanding the Differences

Beyond efficacy differences, these medications vary in dosing schedules, side effect profiles, and cost considerations. Mounjaro starts at a 2.5mg weekly dose, gradually titrating to 5mg, 7.5mg, 10mg, 12.5mg, or 15mg based on tolerance and response. Wegovy follows a similar escalation from 0.25mg to a maintenance dose of 2.4mg weekly.

Saxenda requires daily subcutaneous injections, starting at 0.6mg and increasing over five weeks to the maintenance dose of 3mg. The daily injection schedule provides more consistent blood levels but demands greater adherence compared to weekly alternatives.

Gastrointestinal side effects—nausea, diarrhoea, constipation, and vomiting—are common across all GLP-1 treatments, particularly during dose escalation. These typically diminish after several weeks as your body adapts. Gradual dose titration minimises side effect severity, which is why all three medications follow structured escalation protocols [1][2][3].

Pricing Transparency at Cured Pharmacy

We display all treatment costs upfront before you begin your consultation. Mounjaro is priced from £135.00 per pen, with final cost depending on your prescribed maintenance dose. This transparent pricing model eliminates surprise charges and allows you to make informed decisions about your weight loss investment.

Many UK patients find online pharmacy pricing more competitive than traditional private clinic consultations, which often include separate fees for appointments, prescriptions, and dispensing. At Cured Pharmacy, the consultation is provided free of charge, and you only pay for your medication if a prescription is issued.

Next Day Delivery and Discreet Packaging

Once your prescription is approved and dispensed, medications are shipped via tracked courier services offering next-day delivery across the UK. All weight loss injections require refrigeration, so we use temperature-controlled packaging with gel ice packs to maintain the cold chain during transit.

Upon receipt, store your pens in the refrigerator at 2-8°C immediately. Do not freeze the medication, as this degrades the active ingredient. Each pen should be discarded 28 days after first use, even if solution remains. Proper storage ensures medication potency and reduces the risk of injection site reactions.

Our packaging contains no external branding or content descriptions, ensuring complete discretion. Neighbours, flatmates, and delivery personnel cannot identify the contents as medication. This privacy consideration is particularly valued by patients who prefer to keep their weight loss journey confidential.

Combining Weight Loss Injections with Lifestyle Changes

GLP-1 receptor agonists are not standalone solutions. Clinical trials demonstrating significant weight loss included structured lifestyle interventions—reduced calorie intake and increased physical activity [1][2]. The medications work by reducing appetite and cravings, making it easier to adhere to dietary changes, but they cannot compensate for unchanged eating patterns.

NICE recommends a 500-600 calorie daily deficit alongside GLP-1 treatment, typically achieved through portion control and nutrient-dense food choices rather than extreme restriction [4]. Regular physical activity—at least 150 minutes of moderate-intensity exercise weekly—enhances weight loss outcomes and improves cardiovascular health markers independently of weight reduction.

Your prescriber may recommend follow-up consultations to monitor progress, adjust dosing, and provide ongoing support. Weight loss is rarely linear; plateaus and fluctuations are normal. Sustainable results require patience, consistency, and realistic expectations. Most patients continue treatment for 12-24 months to achieve and consolidate their target weight before considering maintenance strategies.

Managing Side Effects Effectively

Nausea, the most commonly reported side effect, can be minimised by eating smaller, more frequent meals and avoiding high-fat foods which delay gastric emptying further. Staying well-hydrated and avoiding lying down immediately after eating also helps. If nausea persists beyond the first month, consult your prescriber about dose adjustment.

Constipation affects approximately 20-30% of users and responds well to increased fibre intake, adequate hydration, and regular physical activity [1]. Over-the-counter remedies like lactulose or senna may be used short-term if needed. Conversely, some patients experience diarrhoea, which usually resolves within two weeks as your digestive system adapts to altered gastric motility.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications.